Read the latest press releases from Calliditas Therapeutics by clicking on a title below.

For press enquiries please contact us.

CEO Renée Aguiar-Lucander exercises warrants and invests SEK 15.7m (appr. USD 1.7m) in Calliditas

Calliditas provides a corporate business update in the context of the Covid-19 pandemic

Calliditas strengthens its US Commercial Organization

Positive opinion received from EMA Paediatric Committee on the Paediatric Investigation Plan for Nefecon for the treatment of IgAN

Calliditas Therapeutics AB
Kungsbron 1, C8
SE-111 22 Stockholm
Sweden

Company number: 556659-9766

© Calliditas Therapeutics AB 2020